Advertisement
Person › Details
John Baldoni (GlaxoSmithKline plc (LSE: GSK, NYSE: GSK))
Baldoni, John (GSK 201205 SVP Platform + Technology Science)
Organisation | GlaxoSmithKline plc (LSE: GSK, NYSE: GSK) | |
Today | GSK plc (LSE: GSK, NYSE: GSK) | |
Group | GSK (Group) | |
Product | drug discovery technology | |
Product 2 | drug development technology | |
Record changed: 2018-02-20 |
Advertisement
More documents for John Baldoni
- [1] GlaxoSmithKline plc. (10/27/17). "Press Release: Public-private Consortium Aims to Cut Preclinical Cancer Drug Discovery from Six Years to Just One". San Francisco, CA....
- [2] Exscientia Ltd.. (7/2/17). "Press Release: Exscientia Enters Strategic Drug Discovery Collaboration with GSK. Pre-clinical Collaboration Focused on up to 10 Targets Nominated by GSK"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top